Nitya Shree1, Sunil Venkategowda2, M V Venkatranganna3, Indrani Datta4, Ramesh R Bhonde5,6. 1. School of Regenerative Medicine, Manipal Academy of Higher Education, Bangalore, India. 2. Department of Biotechnology, Jain University, Bangalore, India. 3. Connexios Life Sciences Pvt. Ltd., Bangalore, India. 4. Department of Biophysics, NIMHANS, Bangalore, India. 5. School of Regenerative Medicine, Manipal Academy of Higher Education, Bangalore, India. rrbhonde@gmail.com. 6. Dr. D.Y. Patil Vidyapeeth, Pune, India. rrbhonde@gmail.com.
Abstract
OBJECTIVE: Obesity induced metabolic dysregulation results in cluster of chronic conditions mainly hyperglycemia, hyperinsulinemia, dyslipidemia, diabetes, cardiovascular complications and insulin resistance. To investigate the effect of i.m. injection of human adipose tissue derived mesenchymal stem cells and its secretome in correcting obesity induced metabolic dysregulation in high fat diet fed obese model of mice and understand its mechanism of action. SUBJECTS: We injected human adipose tissue derived mesenchymal stem cells (ADMSCs) suspension (CS), conditioned medium (CM) and the cell lysate (CL) intramuscularly in high fat diet (HFD)-induced C57BL/6 mice. Metformin was used as a positive control. ADMSCs were traced in vivo for its bio distribution after injection at different time points. RESULTS: ADMSCs-treated mice exhibited remarkable decrease in insulin resistance as quantified by HOMA-IR and triglyceride glucose index with concomitant decrease in oxidized LDL and IL6 as compared with the untreated control. CS injection showed improvement in glucose tolerance and reduction in fatty infiltration in the liver, macrophage infiltration in adipose and hypertrophy of the islets resulting from HFD. Upregulation of miRNA-206, MyoD and increase in protein content of the skeletal muscle in CS-treated mice indicates plausible mechanism of action of ADMSCs treatment in ameliorating IR in HFD mice. CONCLUSION: Of all the three treatments, CS was found to be the best. ADMSCs were found to have migrated to different organs in order to bring about the correction in dysregulated metabolism induced by obesity. Our results open up a novel treatment modality for possible therapeutic usage in human subjects by employing autologous or allogeneic ADMSCs for the better management of obesity induced metabolic dysregulation.
OBJECTIVE:Obesity induced metabolic dysregulation results in cluster of chronic conditions mainly hyperglycemia, hyperinsulinemia, dyslipidemia, diabetes, cardiovascular complications and insulin resistance. To investigate the effect of i.m. injection of human adipose tissue derived mesenchymal stem cells and its secretome in correcting obesity induced metabolic dysregulation in high fat diet fed obese model of mice and understand its mechanism of action. SUBJECTS: We injected human adipose tissue derived mesenchymal stem cells (ADMSCs) suspension (CS), conditioned medium (CM) and the cell lysate (CL) intramuscularly in high fat diet (HFD)-induced C57BL/6 mice. Metformin was used as a positive control. ADMSCs were traced in vivo for its bio distribution after injection at different time points. RESULTS: ADMSCs-treated mice exhibited remarkable decrease in insulin resistance as quantified by HOMA-IR and triglycerideglucose index with concomitant decrease in oxidized LDL and IL6 as compared with the untreated control. CS injection showed improvement in glucose tolerance and reduction in fatty infiltration in the liver, macrophage infiltration in adipose and hypertrophy of the islets resulting from HFD. Upregulation of miRNA-206, MyoD and increase in protein content of the skeletal muscle in CS-treated mice indicates plausible mechanism of action of ADMSCs treatment in ameliorating IR in HFD mice. CONCLUSION: Of all the three treatments, CS was found to be the best. ADMSCs were found to have migrated to different organs in order to bring about the correction in dysregulated metabolism induced by obesity. Our results open up a novel treatment modality for possible therapeutic usage in human subjects by employing autologous or allogeneic ADMSCs for the better management of obesity induced metabolic dysregulation.
Authors: Lauren Boland; Laura Melanie Bitterlich; Andrew E Hogan; James A Ankrum; Karen English Journal: Front Immunol Date: 2022-07-04 Impact factor: 8.786
Authors: Amy F Boushra; Rania H Mahmoud; Shymaa E Ayoub; Rehab A Mohammed; Hanan A Shamardl; Amani M El Amin Ali Journal: J Diabetes Res Date: 2022-01-17 Impact factor: 4.011
Authors: Xiang-Yang Zhu; Nattawat Klomjit; Sabena M Conley; Megan M Ostlie; Kyra L Jordan; Amir Lerman; Lilach O Lerman Journal: J Cell Mol Med Date: 2021-08-21 Impact factor: 5.310
Authors: Quan Li; Guangyan Qi; Dylan Lutter; Warren Beard; Camila R S Souza; Margaret A Highland; Wei Wu; Ping Li; Yuanyuan Zhang; Anthony Atala; Xiuzhi Sun Journal: Biomolecules Date: 2022-09-17